Research programme: antibody therapeutics - Philogen

Drug Profile

Research programme: antibody therapeutics - Philogen

Alternative Names: Dodecal; F8-IL12; F8-IL4; IL 12-L19-L19; Tetravil

Latest Information Update: 22 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Interleukin 12 stimulants; Interleukin 4 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Endometriosis; Rheumatoid arthritis

Most Recent Events

  • 20 Jan 2016 Preclinical trials in Cancer in Italy (Parenteral) before January 2016 (Philogen website, January 2016)
  • 20 Jan 2016 Preclinical trials in Endometriosis in Italy (Parenteral) before January 2016 (Philogen Pipeline, January 2016)
  • 20 Jan 2016 Philogen plans clinical trials for Rheumatoid arthritis and Endometriosis in Europe (Parenteral) (Philogen website, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top